Company Report
29 October 2026
ANTM’s 9M26 results were in line, with revenue of IDR 88.48 tn (+22.8% YoY, 74.3% of ou...
Company Report
29 October 2026
BBCA continued to deliver resilient earnings in 9M26, with profit growth gaining moment...
23 November 2021
Bank Mandiri Tbk (BMRI) managed to book a net profit of IDR 19.3 trillion in 9M21, an increase of 37.1% YoY. This increase was supported by solid growth in Net Interest Income and Non-Interest Income. The company is still optimistic that credit disbursement can increase by double digits until the end of 2021, with NIM level in line with our estimates.
22 November 2021
Meanwhile, profit jumped 316% YoY. PTPP revised down the new contracts to IDR27.8 trillion, in which PTPP has acquired IDR13.48 trillion of new contracts or 48.4% of the target. In the future, PTPP will aim for the National Strategic Project (PSN) in the infrastructure and EPC field with a target contract of IDR5.9 trillion.
10 November 2021
INCO posted a robust sales of US$687.2 million and net earnings of US$122.3 million in 9M-21. The result was supported by higher ASP, which follows the uptrend in nickel prices globally. Previously, we suspect crude oil and coal prices growth will increase INCO’s operational costs and thus hinder their performance, but INCO’s better than expected results in 9M21 allow us to give overweight recommendation for INCO.
9 November 2021
MIKA continues to booked solid performance in 9M21 with strong growth in both inpatient and outpatient segments. For upcoming quarters, we expect there will be normalization of margin and patient traffic volume after Covid-19 peak. Given its strong track record and balance sheet, we believe company’s strategic plan will be achievable.
8 November 2021
BBNI booked a net profit of IDR 7.7 trillion throughout 9M21, or 79.4% of our estimates of IDR 9.7 trillion. The performance was supported by a decline in interest expense and NPL. LAR ratio fell as domestic economy recovers, resulting in BBNI was able to control NPL ratio for the rest of the year. NHKSI Research maintains BUY recommendation by raising our TP to IDR 9,000/share.
